why does nobody talk about biopsy
Slightly embarrassed to be asking this, but: why does nobody talk about biopsy. Bought small because the evidence base is early. That is the only defensible position I could construct. The honest evidence position, written out so this board does not drift. Phase 2 data exists in a specific, biopsy-characterised…
Is that a weight number from a different programme?
Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.
MASH endpoints are histological, which is a much harder bar
this board is small because the compound is early
This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.
Right, and the trial titration was slow for reasons that are visible in the tolerability tables.